This is the second time in a matter of weeks the FDA has approved an RDN system for uncontrolled hypertension. The SCAI issued a statement about this trend, calling it a “game-changer for both interventional cardiology and the treatment of hypertension."

The COVID-19 pandemic undid years and years of progress in terms of preventing CVD-related deaths. What can be done to help reverse this trend once and for all? 

He has agreed to pay an administrative fee of $1,100 within the next three months.

“Nearly 300,000 cardiac arrests occur in hospitals in the United States each year, and only about 25% of people survive to hospital discharge after these types of events,” according to one author of a new analysis published in Circulation: Cardiovascular Quality and Outcomes.

One key difference between this new risk calculator and previous methods is that it does not consider a patient's race or ethnicity. It does, however, consider such factors as where the patient lives, their education and their income level. 

The FDA issued its own statement about the approval, highlighting the importance of taking the drug in combination with an improved diet and regular physical activity.  

Ultromics thinks the significant payment increase will help ramp up utilization among U.S. healthcare providers.

The system, designed for patients with uncontrolled hypertension who are unresponsive to medication, uses ultrasound ablation to target nerves in the renal arteries, increasing blood flow. This approval comes just months after an FDA advisory panel voted in favor of the system.